vs
渤健（BIIB）与Ovintiv Inc.（OVV）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Ovintiv Inc.的1.1倍（$2.3B vs $2.1B），Ovintiv Inc.净利率更高（46.1% vs -2.1%，领先48.2%），Ovintiv Inc.同比增速更快（-6.0% vs -7.1%），Ovintiv Inc.自由现金流更多（$489.0M vs $468.0M），过去两年渤健的营收复合增速更高（-0.2% vs -7.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Ovintiv Inc.是一家总部位于美国丹佛的石油企业，前身为加拿大能源公司Encana，于2020年通过重组正式成立，主营石油、天然气的勘探、开发与生产业务，在北美能源领域拥有丰富的运营经验及市场积累。
BIIB vs OVV — 直观对比
营收规模更大
BIIB
是对方的1.1倍
$2.1B
营收增速更快
OVV
高出1.1%
-7.1%
净利率更高
OVV
高出48.2%
-2.1%
自由现金流更多
OVV
多$21.0M
$468.0M
两年增速更快
BIIB
近两年复合增速
-7.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.1B |
| 净利润 | $-48.9M | $946.0M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | 21.2% |
| 净利率 | -2.1% | 46.1% |
| 营收同比 | -7.1% | -6.0% |
| 净利润同比 | -118.3% | 1676.7% |
| 每股收益（稀释后） | $-0.35 | $3.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBOVV
| Q4 25 | $2.3B | $2.1B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $2.2B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.5B | $2.2B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $2.2B | ||
| Q1 24 | $2.3B | $2.4B |
净利润BIIBOVV
| Q4 25 | $-48.9M | $946.0M | ||
| Q3 25 | $466.5M | $148.0M | ||
| Q2 25 | $634.8M | $307.0M | ||
| Q1 25 | $240.5M | $-159.0M | ||
| Q4 24 | $266.7M | $-60.0M | ||
| Q3 24 | $388.5M | $507.0M | ||
| Q2 24 | $583.6M | $340.0M | ||
| Q1 24 | $393.4M | $338.0M |
毛利率BIIBOVV
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBOVV
| Q4 25 | -2.5% | 21.2% | ||
| Q3 25 | 22.0% | 13.5% | ||
| Q2 25 | 28.1% | 23.1% | ||
| Q1 25 | 12.8% | -3.7% | ||
| Q4 24 | 11.9% | 0.1% | ||
| Q3 24 | 18.3% | 24.2% | ||
| Q2 24 | 28.3% | 25.4% | ||
| Q1 24 | 20.3% | 20.7% |
净利率BIIBOVV
| Q4 25 | -2.1% | 46.1% | ||
| Q3 25 | 18.4% | 7.3% | ||
| Q2 25 | 24.0% | 13.9% | ||
| Q1 25 | 9.9% | -6.7% | ||
| Q4 24 | 10.9% | -2.7% | ||
| Q3 24 | 15.8% | 23.3% | ||
| Q2 24 | 23.7% | 15.5% | ||
| Q1 24 | 17.2% | 14.2% |
每股收益（稀释后）BIIBOVV
| Q4 25 | $-0.35 | $3.64 | ||
| Q3 25 | $3.17 | $0.57 | ||
| Q2 25 | $4.33 | $1.18 | ||
| Q1 25 | $1.64 | $-0.61 | ||
| Q4 24 | $1.82 | $-0.22 | ||
| Q3 24 | $2.66 | $1.92 | ||
| Q2 24 | $4.00 | $1.27 | ||
| Q1 24 | $2.70 | $1.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $280.0M |
| 总债务越低越好 | $6.3B | $5.2B |
| 股东权益账面价值 | $18.3B | $11.2B |
| 总资产 | $29.4B | $20.4B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.46× |
8季度趋势，按日历期对齐
现金及短期投资BIIBOVV
| Q4 25 | — | $280.0M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | — | $20.0M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | — | $9.0M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $5.0M |
总债务BIIBOVV
| Q4 25 | $6.3B | $5.2B | ||
| Q3 25 | $6.3B | $5.2B | ||
| Q2 25 | $6.3B | $5.3B | ||
| Q1 25 | $4.5B | $5.5B | ||
| Q4 24 | $6.3B | $5.5B | ||
| Q3 24 | $4.5B | $5.9B | ||
| Q2 24 | $6.3B | $6.1B | ||
| Q1 24 | $6.3B | $6.2B |
股东权益BIIBOVV
| Q4 25 | $18.3B | $11.2B | ||
| Q3 25 | $18.2B | $10.2B | ||
| Q2 25 | $17.6B | $10.4B | ||
| Q1 25 | $17.0B | $10.1B | ||
| Q4 24 | $16.7B | $10.3B | ||
| Q3 24 | $16.4B | $10.7B | ||
| Q2 24 | $15.9B | $10.3B | ||
| Q1 24 | $15.2B | $10.3B |
总资产BIIBOVV
| Q4 25 | $29.4B | $20.4B | ||
| Q3 25 | $29.2B | $19.4B | ||
| Q2 25 | $28.3B | $19.7B | ||
| Q1 25 | $28.0B | $19.6B | ||
| Q4 24 | $28.0B | $19.3B | ||
| Q3 24 | $28.3B | $19.9B | ||
| Q2 24 | $26.8B | $19.8B | ||
| Q1 24 | $26.6B | $19.8B |
负债/权益比BIIBOVV
| Q4 25 | 0.34× | 0.46× | ||
| Q3 25 | 0.35× | 0.51× | ||
| Q2 25 | 0.36× | 0.51× | ||
| Q1 25 | 0.27× | 0.55× | ||
| Q4 24 | 0.38× | 0.53× | ||
| Q3 24 | 0.28× | 0.55× | ||
| Q2 24 | 0.40× | 0.59× | ||
| Q1 24 | 0.41× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $954.0M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $489.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 23.8% |
| 资本支出强度资本支出/营收 | 1.9% | 22.6% |
| 现金转化率经营现金流/净利润 | — | 1.01× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $1.5B |
8季度趋势，按日历期对齐
经营现金流BIIBOVV
| Q4 25 | $511.9M | $954.0M | ||
| Q3 25 | $1.3B | $812.0M | ||
| Q2 25 | $160.9M | $1.0B | ||
| Q1 25 | $259.3M | $873.0M | ||
| Q4 24 | $760.9M | $1.0B | ||
| Q3 24 | $935.6M | $1.0B | ||
| Q2 24 | $625.8M | $1.0B | ||
| Q1 24 | $553.2M | $659.0M |
自由现金流BIIBOVV
| Q4 25 | $468.0M | $489.0M | ||
| Q3 25 | $1.2B | $268.0M | ||
| Q2 25 | $134.3M | $492.0M | ||
| Q1 25 | $222.2M | $256.0M | ||
| Q4 24 | $721.6M | $468.0M | ||
| Q3 24 | $900.6M | $484.0M | ||
| Q2 24 | $592.3M | $398.0M | ||
| Q1 24 | $507.3M | $68.0M |
自由现金流率BIIBOVV
| Q4 25 | 20.5% | 23.8% | ||
| Q3 25 | 48.4% | 13.3% | ||
| Q2 25 | 5.1% | 22.2% | ||
| Q1 25 | 9.1% | 10.8% | ||
| Q4 24 | 29.4% | 21.4% | ||
| Q3 24 | 36.5% | 22.2% | ||
| Q2 24 | 24.0% | 18.1% | ||
| Q1 24 | 22.1% | 2.8% |
资本支出强度BIIBOVV
| Q4 25 | 1.9% | 22.6% | ||
| Q3 25 | 1.8% | 26.9% | ||
| Q2 25 | 1.0% | 23.5% | ||
| Q1 25 | 1.5% | 26.0% | ||
| Q4 24 | 1.6% | 25.3% | ||
| Q3 24 | 1.4% | 24.7% | ||
| Q2 24 | 1.4% | 28.4% | ||
| Q1 24 | 2.0% | 24.8% |
现金转化率BIIBOVV
| Q4 25 | — | 1.01× | ||
| Q3 25 | 2.73× | 5.49× | ||
| Q2 25 | 0.25× | 3.30× | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | 2.02× | ||
| Q2 24 | 1.07× | 3.00× | ||
| Q1 24 | 1.41× | 1.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
OVV
| Product And Service Revenue | $1.7B | 84% |
| Sales Of Purchased Product | $338.0M | 16% |
